XML 77 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table
Pay Versus Performance
 
 
As required, below is disclosure of the compensation of the Company’s Named Executive Officers, or NEOs, for the last four fiscal years calculated in accordance with Item 402(v) of Regulation S-K. Item 402(v) requires disclosure of “compensation actually paid” based on calculations that report changes in the fair value of equity awards granted in prior years, granted during the fiscal year, and vesting during the fiscal year, but
that do not reflect the actual amount of compensation earned or received by any of the NEOs during the fiscal year.
For information about our compensation philosophy and how we align executive compensation with our performance, please see our Compensation Discussion and Analysis.
 
Year
                          
Value of Initial Fixed $100
Investment Based on:
              
 
Summary
Compensation
Table Total for
CEO($)
    
Compensation
Actually Paid to
CEO($)
(1)(2)
    
Average
Summary
Compensation
Table Total for
non-CEO

Named
Executive
Officers($)
    
Average
Compensation
Actually Paid to
Non-CEO
Named
Executive
Officers
(1)(2)
    
Amgen Total
Shareholder
Return($)
(3)
    
Peer Group
Total
Shareholder
Return($)
(3)(4)
    
Net
Income
($M)
    
Non-GAAP
EPS($)
(5)
  
2023
     22,643,650       29,105,407       7,730,150       9,701,292       135.10       140.78       6,717       18.65  
2022
     21,399,733       41,655,553       7,211,427       12,777,767       119.07       140.14       6,552       17.69  
2021
     21,721,154       17,040,728       7,358,134       5,869,521       98.87       126.48       5,893       17.10  
2020
     20,131,408       14,724,312       6,736,942       5,571,375       98.01       102.57       7,264       16.60  
 
(1)
 
As the valuation methods for “compensation actually paid” required by the SEC differ from those required in the Summary Compensation Table (“SCT”), the table below provides a reconciliation of SCT amounts to the Compensation Actually Paid (“CAP”) amounts in the Pay Versus Performance table for Mr. Bradway and the average SCT and CAP amounts for our other NEOs for each of the last four fiscal years. The other non-CEO NEOs for each of 2023, 2022, 2021, and 2020 include Messrs. Gordon, Griffith, and Santos and Dr. Reese.
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
 
               
Required Adjustments to Summary Compensation Table Totals to Determine
“Compensation Actually Paid”
        
   
Year
    
Summary
Compensation
Table Total($)
    
Summary
Compensation
Table Value
of Stock
Awards($)
    
Summary
Compensation
Table
Value of
Option
Awards($)
    
Fair Value as
of Year End of
Equity Awards
Granted
During the
Year($)
    
Year-Over-Year

Increase
(Decrease) in
Fair Value as of
Year End of
Unvested
Awards Granted
in Prior Years($)
    
Increase
(Decrease)
From Prior Year
End in Fair
Value of
Awards That
Vested During
the Year($)
    
Compensation Actually
Paid($)
  
         
(a)
    
(b)
    
(c)
    
(d)
    
(e)
    
(f)
    
(g)=(a)-(b)-(c)+(d)+(e)+(f)
  
Robert A. Bradway
     2023       22,643,650       11,138,503       4,773,714       23,595,558       1,094,746       (2,316,330 )      29,105,407  
    2022       21,399,733       11,138,544       4,773,714       20,800,961       11,751,273       3,615,844       41,655,553  
    2021       21,721,154       11,138,622       4,773,710       13,805,997       (2,572,161 )      (1,930 )      17,040,728  
    2020       20,131,408       10,079,676       4,319,993       13,341,787       (3,546,758 )      (802,456 )      14,724,312  
Average of Other NEOs
     2023       7,730,150       3,184,835       1,364,981       6,746,746       294,430       (520,218 )      9,701,292  
    2022       7,211,427       3,184,719       1,364,984       5,947,522       3,219,024       949,497       12,777,767  
    2021       7,358,134       3,246,014       1,391,226       4,023,392       (640,566 )      (234,199 )      5,869,521  
    2020       6,736,942       2,834,702       1,214,968       3,752,153       (650,362 )      (217,688 )      5,571,375  
 
(2)
 
Stock option fair values are calculated at each measurement date using a Black-Scholes valuation model, consistent with the approach used to value the awards at the grant date. Stock option fair values as of each measurement date were determined using updated assumptions (the closing stock price of our Common Stock as of the measurement date, risk-free interest rate, expected life, expected volatility of the price of our Common Stock, and expected dividend yield) and changes in fair value are primarily driven by increases or decreases in the price of the Company’s Common Stock as of each measurement date.
 
 
 
Performance unit fair values are calculated using a payout simulation model, consistent with the approach used to value the awards at the grant date. Performance unit fair values as of each measurement date were determined using updated assumptions (risk-free interest rate, volatility of the price of our Common Stock, the closing price of our Common Stock on the measurement date, volatilities of the prices of the stocks of the Reference Group (as defined in footnote 3 to the “Grant of Plan-Based Awards” table in our Executive Compensation Tables), and the correlations of returns of our Common Stock and the stocks of the Reference Group to simulate total shareholder returns and their resulting impact on the payout percentages based on the contractual terms of the performance units) and changes in fair value are primarily driven by increases or decreases in the price of the Company’s Common Stock as of each measurement date.
 
(3)
 
Pursuant to the SEC rules, total shareholder return, or TSR, reflects an initial investment of $100 on December 31, 2019. All values assume reinvestment of the pretax value of dividends, are calculated as of December 31 of each year, and are weighted according to the respective issuers’ stock market capitalization at the beginning of each period for which a return is indicated.
 
(4)
 
The peer group for each listed fiscal year consists of the companies listed as our executive compensation benchmarking peer group in the Compensation Discussion and Analysis specific for that year. For 2020, the companies included: Allergan plc (until July 2020); Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Celgene Corporation (until July 2020); Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A. For 2021, 2022, and 2023, the peer group included: Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A.
 
(5)
 
Non-Generally Accepted Accounting Principles, or non-GAAP, earnings per share for purposes of the Company selected measure is reported and reconciled in
Appendix B
. For 2020, non-GAAP earnings per share is reported and reconciled in Appendix B to our 2023 proxy statement filed with the SEC on April 6, 2023.
     
Company Selected Measure Name non-GAAP, earnings per share      
Named Executive Officers, Footnote The other non-CEO NEOs for each of 2023, 2022, 2021, and 2020 include Messrs. Gordon, Griffith, and Santos and Dr. Reese.      
Peer Group Issuers, Footnote The peer group for each listed fiscal year consists of the companies listed as our executive compensation benchmarking peer group in the Compensation Discussion and Analysis specific for that year. For 2020, the companies included: Allergan plc (until July 2020); Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Celgene Corporation (until July 2020); Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A. For 2021, 2022, and 2023, the peer group included: Abbvie, Inc.; AstraZeneca plc; Biogen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Sanofi S.A.      
PEO Total Compensation Amount $ 22,643,650 $ 21,399,733 $ 21,721,154 $ 20,131,408
PEO Actually Paid Compensation Amount $ 29,105,407 41,655,553 17,040,728 14,724,312
Adjustment To PEO Compensation, Footnote
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
 
               
Required Adjustments to Summary Compensation Table Totals to Determine
“Compensation Actually Paid”
        
   
Year
    
Summary
Compensation
Table Total($)
    
Summary
Compensation
Table Value
of Stock
Awards($)
    
Summary
Compensation
Table
Value of
Option
Awards($)
    
Fair Value as
of Year End of
Equity Awards
Granted
During the
Year($)
    
Year-Over-Year

Increase
(Decrease) in
Fair Value as of
Year End of
Unvested
Awards Granted
in Prior Years($)
    
Increase
(Decrease)
From Prior Year
End in Fair
Value of
Awards That
Vested During
the Year($)
    
Compensation Actually
Paid($)
  
         
(a)
    
(b)
    
(c)
    
(d)
    
(e)
    
(f)
    
(g)=(a)-(b)-(c)+(d)+(e)+(f)
  
Robert A. Bradway
     2023       22,643,650       11,138,503       4,773,714       23,595,558       1,094,746       (2,316,330 )      29,105,407  
    2022       21,399,733       11,138,544       4,773,714       20,800,961       11,751,273       3,615,844       41,655,553  
    2021       21,721,154       11,138,622       4,773,710       13,805,997       (2,572,161 )      (1,930 )      17,040,728  
    2020       20,131,408       10,079,676       4,319,993       13,341,787       (3,546,758 )      (802,456 )      14,724,312  
Average of Other NEOs
     2023       7,730,150       3,184,835       1,364,981       6,746,746       294,430       (520,218 )      9,701,292  
    2022       7,211,427       3,184,719       1,364,984       5,947,522       3,219,024       949,497       12,777,767  
    2021       7,358,134       3,246,014       1,391,226       4,023,392       (640,566 )      (234,199 )      5,869,521  
    2020       6,736,942       2,834,702       1,214,968       3,752,153       (650,362 )      (217,688 )      5,571,375  
      
Non-PEO NEO Average Total Compensation Amount $ 7,730,150 7,211,427 7,358,134 6,736,942
Non-PEO NEO Average Compensation Actually Paid Amount $ 9,701,292 12,777,767 5,869,521 5,571,375
Adjustment to Non-PEO NEO Compensation Footnote
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
 
               
Required Adjustments to Summary Compensation Table Totals to Determine
“Compensation Actually Paid”
        
   
Year
    
Summary
Compensation
Table Total($)
    
Summary
Compensation
Table Value
of Stock
Awards($)
    
Summary
Compensation
Table
Value of
Option
Awards($)
    
Fair Value as
of Year End of
Equity Awards
Granted
During the
Year($)
    
Year-Over-Year

Increase
(Decrease) in
Fair Value as of
Year End of
Unvested
Awards Granted
in Prior Years($)
    
Increase
(Decrease)
From Prior Year
End in Fair
Value of
Awards That
Vested During
the Year($)
    
Compensation Actually
Paid($)
  
         
(a)
    
(b)
    
(c)
    
(d)
    
(e)
    
(f)
    
(g)=(a)-(b)-(c)+(d)+(e)+(f)
  
Robert A. Bradway
     2023       22,643,650       11,138,503       4,773,714       23,595,558       1,094,746       (2,316,330 )      29,105,407  
    2022       21,399,733       11,138,544       4,773,714       20,800,961       11,751,273       3,615,844       41,655,553  
    2021       21,721,154       11,138,622       4,773,710       13,805,997       (2,572,161 )      (1,930 )      17,040,728  
    2020       20,131,408       10,079,676       4,319,993       13,341,787       (3,546,758 )      (802,456 )      14,724,312  
Average of Other NEOs
     2023       7,730,150       3,184,835       1,364,981       6,746,746       294,430       (520,218 )      9,701,292  
    2022       7,211,427       3,184,719       1,364,984       5,947,522       3,219,024       949,497       12,777,767  
    2021       7,358,134       3,246,014       1,391,226       4,023,392       (640,566 )      (234,199 )      5,869,521  
    2020       6,736,942       2,834,702       1,214,968       3,752,153       (650,362 )      (217,688 )      5,571,375  
      
Compensation Actually Paid vs. Total Shareholder Return
(1)
   
Compensation Actually Paid Compared to Total Shareholder Return
 
  
     
Compensation Actually Paid vs. Net Income
 
(2)
   
 
Compensation Actually Paid Compared to Net Income
 
  
     
Compensation Actually Paid vs. Company Selected Measure
 
(3)
   
 
Compensation Actually Paid Compared to Non-GAAP Earnings
Per
Share
 
  
     
Total Shareholder Return Vs Peer Group
(1)
   
Compensation Actually Paid Compared to Total Shareholder Return
 
  
     
Tabular List, Table
2023 Performance Measures
Pursuant to Item 402(v) of Regulation S-K, the Compensation Committee identified the following financial and non-financial performance measures used in our long-term and annual incentive programs as representing the most important performance measures used to link “compensation actually paid” in 2023 to the Company’s performance.
 
•
   Non-GAAP earnings per share (EPS)
•
   Non-GAAP return on invested capital (ROIC)
•
   Total shareholder return (TSR) relative to that of the S&P 500
•
   Revenues
   
•
   Non-GAAP net income
•
   Pipeline, clinical study, and regulatory goals
•
   Environmental, social, and governance goals
For a description of these measures and their application to our compensation programs for 2023, please see our Compensation Discussion and Analysis.
     
Total Shareholder Return Amount $ 135.1 119.07 98.87 98.01
Peer Group Total Shareholder Return Amount 140.78 140.14 126.48 102.57
Net Income (Loss) $ 6,717,000,000 $ 6,552,000,000 $ 5,893,000,000 $ 7,264,000,000
Company Selected Measure Amount 18.65 17.69 17.1 16.6
PEO Name Mr. Bradway      
Measure:: 1        
Pay vs Performance Disclosure        
Name Non-GAAP earnings per share (EPS)      
Non-GAAP Measure Description Non-Generally Accepted Accounting Principles, or non-GAAP, earnings per share for purposes of the Company selected measure is reported and reconciled in
Appendix B
. For 2020, non-GAAP earnings per share is reported and reconciled in Appendix B to our 2023 proxy statement filed with the SEC on April 6, 2023. 		     
Measure:: 2        
Pay vs Performance Disclosure        
Name Non-GAAP return on invested capital (ROIC)      
Measure:: 3        
Pay vs Performance Disclosure        
Name Total shareholder return (TSR) relative to that of the S&P 500      
Measure:: 4        
Pay vs Performance Disclosure        
Name Revenues      
Measure:: 5        
Pay vs Performance Disclosure        
Name Non-GAAP net income      
Measure:: 6        
Pay vs Performance Disclosure        
Name Pipeline, clinical study, and regulatory goals      
Measure:: 7        
Pay vs Performance Disclosure        
Name Environmental, social, and governance goals      
PEO | Summary Compensation Table Value of Stock Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 11,138,503 $ 11,138,544 $ 11,138,622 $ 10,079,676
PEO | Summary Compensation Table Value of Option Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 4,773,714 4,773,714 4,773,710 4,319,993
PEO | Fair Value as of Year End of Equity Awards Granted During the Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 23,595,558 20,800,961 13,805,997 13,341,787
PEO | Year-Over-Year Increase (Decrease) in Fair Value as of Year End of Unvested Awards Granted in Prior Years [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,094,746 11,751,273 (2,572,161) (3,546,758)
PEO | Increase (Decrease) From Prior Year End in Fair Value of Awards That Vested During the Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (2,316,330) 3,615,844 (1,930) (802,456)
Non-PEO NEO | Summary Compensation Table Value of Stock Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 3,184,835 3,184,719 3,246,014 2,834,702
Non-PEO NEO | Summary Compensation Table Value of Option Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,364,981 1,364,984 1,391,226 1,214,968
Non-PEO NEO | Fair Value as of Year End of Equity Awards Granted During the Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 6,746,746 5,947,522 4,023,392 3,752,153
Non-PEO NEO | Year-Over-Year Increase (Decrease) in Fair Value as of Year End of Unvested Awards Granted in Prior Years [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 294,430 3,219,024 (640,566) (650,362)
Non-PEO NEO | Increase (Decrease) From Prior Year End in Fair Value of Awards That Vested During the Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ (520,218) $ 949,497 $ (234,199) $ (217,688)